ArticleBMC microbiology2026
Unraveling a new Klebsiella phage KP47 against Klebsiella spp.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundThe increase in cases of infectious diseases related to multidrug-resistant bacteria and the spread of multidrug-resistant genes have driven the search for therapeutic alternatives that can circumvent this global phenomenon. One of these alternatives is the use of bacteriophages, which are viruses capable of infecting and killing specific bacteria. Klebsiella pneumoniae species complex (KpSC) is an important opportunistic group associated with multidrug resistance. This group includes Klebsiella quasipneumoniae subsp. similipneumoniae, a species recognized as a clinically relevant pathogen, and that was used as a host (designated Klebsiella KH1) to isolate the phage characterized in the present study. The characterization of new phages is essential to expand the therapeutic arsenal and to improve our understanding on phage diversity. In this study, we evaluated a Klebsiella bacteriophage named KP47 that was isolated from sewage in the United Kingdom. We performed phage biological and genomic characterization in order to assess its therapeutic attributes. KP47 represents a newly isolated Klebsiella phage, being able to infect both K. pneumoniae and K. quasipneumoniae subsp. similipneumoniae, which also shows evidence of depolymerase activity and an efficient bacteriolytic performance.
resultsThe phage KP47 showed a typical morphology of the Caudoviricetes class, with a capsid of 48 nm and a tail of 161 nm. Its genome has 47,396 bp, 63 CDSs, and a GC content of 57.52%, which apparently encodes a depolymerase. ViPTree analysis placed KP47 near Drexlerviridae-related phages, while comparative analyses using representative RefSeq genomes revealed low intergenomic similarity. This phage demonstrated strictly lytic behavior and fast adsorption (90% in 6 min). MOI experiments indicated complete inhibition of bacterial growth in MOIs ≥ 1. The phage infected two out of nine tested strains belonging to the strains of KpSC.
conclusionsIn this study, we described the Klebsiella phage KP47, likely representing a new viral genus, that exhibits a strictly lytic lifestyle, rapid adsorption (90% within 6 min), and an effective bacterial growth inhibition at MOIs ≥ 1. KP47 was able to infect clinically relevant members of the Klebsiella pneumoniae species complex. Further investigations of its potential to act on biofilms and against Klebsiella species in in vivo models are of interest to evaluate its potential for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.